Program
QLC7401
A development code. Also written as “QLC7401 Injection” and “QLC7401 injection”.
Its studies are mostly in Hyperlipoproteinemia Type II · Hypercholesterolemia, led by Qilu Pharmaceutical.
Furthest: phase 3, since Feb 11, 20265 company-led studies, 5 open or runningNext primary completion: Oct 7, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 55 open or running | phase 3since Feb 11, 2026 | Dec 16, 2024 | Oct 7, 2027phase 3 · NCT07444086 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2024First study: phase 2 study in Hyperlipoproteinemia Type IIFirst studyNCT06750341 · 156 planned
- Jul 10, 2025Phase 1 study in Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-CNCT07074236 · 48 planned · China
- Feb 11, 20263 phase 3 studiesPhase 3 reachedNCT07441317, NCT07444086, NCT07450378
Ahead
- Oct 7, 2027Primary completion: phase 3 study in Hyperlipoproteinemia Type IINCT07444086
- Dec 2027Primary completion: phase 3 study in Hyperlipoproteinemia Type IINCT07441317
- Apr 2028Primary completion: phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07450378
TargetBeta
PCSK9 →read by rule
“QLC7401 is a small interfering RNA (siRNA) targeting PCSK9.”study text, by rule · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07450378Heterozygous Familial Hypercholesterolemia (HeFH) | 3 | Not yet recruiting | Apr 2028 | 120 |
| NCT07444086Hyperlipoproteinemia Type II | 3 | Not yet recruiting | Oct 7, 2027 | 510 |
| NCT07441317Hyperlipoproteinemia Type II | 3 | Not yet recruiting | Dec 2027 | 780 |
| NCT07074236Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C · China | 1 | Not yet recruiting | Jan 2026 | 48 |
| NCT06750341Hyperlipoproteinemia Type II | 2 | Not yet recruiting | Jun 2026 | 156 |
How it is read
Names in the registry
- “QLC7401”, 3 entries
- “QLC7401 Injection”, 1 entry
- “QLC7401 injection”, 1 entry
Codes read as this program: QLC7401.
Conditions, from the studies’ own filings
- Hyperlipoproteinemia Type II, 4 studies
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.